Literature DB >> 10729142

Rta of murine gammaherpesvirus 68 reactivates the complete lytic cycle from latency.

T T Wu1, E J Usherwood, J P Stewart, A A Nash, R Sun.   

Abstract

Herpesviruses are characterized as having two distinct life cycle phases: lytic replication and latency. The mechanisms of latency establishment and maintenance, as well as the switch from latency to lytic replication, are poorly understood. Human gammaherpesviruses, including Epstein-Barr virus (EBV) and human herpesvirus-8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus (KSHV), are associated with lymphoproliferative diseases and several human tumors. Unfortunately, the lack of cell lines to support efficient de novo productive infection and restricted host ranges of EBV and HHV-8 make it difficult to explore certain important biological questions. Murine gammaherpesvirus 68 (MHV-68, or gammaHV68) can establish de novo lytic infection in a variety of cell lines and is also able to infect laboratory mice, offering an ideal model with which to study various aspects of gammaherpesvirus infection. Here we describe in vitro studies of the mechanisms of the switch from latency to lytic replication of MHV-68. An MHV-68 gene, rta (replication and transcription activator), encoded primarily by open reading frame 50 (ORF50), is homologous to the rta genes of other gammaherpesviruses, including HHV-8 and EBV. HHV-8 and EBV Rta have been shown to play central roles in viral reactivation from latency. We first studied the kinetics of MHV-68 rta gene transcription during de novo lytic infection. MHV-68 rta was predominantly expressed as a 2-kb immediate-early transcript. Sequence analysis of MHV-68 rta cDNA revealed that an 866-nucleotide intron 5' of ORF50 was removed to create the Rta ORF of 583 amino acids. To test the functions of MHV-68 Rta in reactivation, a plasmid expressing Rta was transfected into a latently infected cell line, S11E, which was established from a B-cell lymphoma in an MHV-68-infected mouse. Rta induced expression of viral early and late genes, lytic replication of viral DNA, and production of infectious viral particles. We conclude that Rta alone is able to disrupt latency, activate viral lytic replication, and drive the lytic cycle to completion. This study indicates that MHV-68 provides a valuable model for investigating regulation of the balance between latency and lytic replication in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10729142      PMCID: PMC111876          DOI: 10.1128/jvi.74.8.3659-3667.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators.

Authors:  S Kenney; E Holley-Guthrie; E C Mar; M Smith
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

2.  The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R.

Authors:  M Buisson; E Manet; M C Trescol-Biemont; H Gruffat; B Durand; A Sergeant
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

3.  The Epstein-Barr virus (EBV) DR enhancer contains two functionally different domains: domain A is constitutive and cell specific, domain B is transactivated by the EBV early protein R.

Authors:  A Chevallier-Greco; H Gruffat; E Manet; A Calender; A Sergeant
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

4.  Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA.

Authors:  J Countryman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

5.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

6.  Synchronous and sequential activation of latently infected Epstein-Barr virus genomes.

Authors:  K Takada; Y Ono
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

7.  An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators.

Authors:  M A Cox; J Leahy; J M Hardwick
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

8.  A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen.

Authors:  J M Hardwick; P M Lieberman; S D Hayward
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

9.  Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter.

Authors:  A Chevallier-Greco; E Manet; P Chavrier; C Mosnier; J Daillie; A Sergeant
Journal:  EMBO J       Date:  1986-12-01       Impact factor: 11.598

10.  Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators.

Authors:  E Manet; H Gruffat; M C Trescol-Biemont; N Moreno; P Chambard; J F Giot; A Sergeant
Journal:  EMBO J       Date:  1989-06       Impact factor: 11.598

View more
  93 in total

1.  Gammaherpesvirus lytic gene expression as characterized by DNA array.

Authors:  Joo Wook Ahn; Kenneth L Powell; Paul Kellam; Dagmar G Alber
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Disruption of gammaherpesvirus 68 gene 50 demonstrates that Rta is essential for virus replication.

Authors:  Iglika V Pavlova; Herbert W Virgin; Samuel H Speck
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Quantitative analysis of long-term virus-specific CD8+-T-cell memory in mice challenged with unrelated pathogens.

Authors:  Haiyan Liu; Samita Andreansky; Gabriela Diaz; Stephen J Turner; Dominik Wodarz; Peter C Doherty
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

4.  Poly(ADP-ribose) polymerase 1 and Ste20-like kinase hKFC act as transcriptional repressors for gamma-2 herpesvirus lytic replication.

Authors:  Yousang Gwack; Hiroyuki Nakamura; Sun Hwa Lee; John Souvlis; Jason T Yustein; Steve Gygi; Hsing-Jien Kung; Jae U Jung
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

5.  Generation of a latency-deficient gammaherpesvirus that is protective against secondary infection.

Authors:  Tammy M Rickabaugh; Helen J Brown; DeeAnn Martinez-Guzman; Ting-Ting Wu; Leming Tong; Fuqu Yu; Steven Cole; Ren Sun
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

6.  COX-2 induction during murine gammaherpesvirus 68 infection leads to enhancement of viral gene expression.

Authors:  Tonia L Symensma; DeeAnn Martinez-Guzman; Qingmei Jia; Eric Bortz; Ting-Ting Wu; Nandini Rudra-Ganguly; Steve Cole; Harvey Herschman; Ren Sun
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

7.  Tiled microarray identification of novel viral transcript structures and distinct transcriptional profiles during two modes of productive murine gammaherpesvirus 68 infection.

Authors:  Benson Yee Hin Cheng; Jizu Zhi; Alexis Santana; Sohail Khan; Eduardo Salinas; J Craig Forrest; Yueting Zheng; Shirin Jaggi; Janet Leatherwood; Laurie T Krug
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

8.  Genome-wide identification of binding sites for Kaposi's sarcoma-associated herpesvirus lytic switch protein, RTA.

Authors:  Jiguo Chen; Fengchun Ye; Jianping Xie; Kurt Kuhne; Shou-Jiang Gao
Journal:  Virology       Date:  2009-02-23       Impact factor: 3.616

9.  Two phenylalanines in the C-terminus of Epstein-Barr virus Rta protein reciprocally modulate its DNA binding and transactivation function.

Authors:  Lee-Wen Chen; Vineetha Raghavan; Pey-Jium Chang; Duane Shedd; Lee Heston; Henri-Jacques Delecluse; George Miller
Journal:  Virology       Date:  2009-02-15       Impact factor: 3.616

10.  Transcription program of murine gammaherpesvirus 68.

Authors:  DeeAnn Martinez-Guzman; Tammy Rickabaugh; Ting-Ting Wu; Helen Brown; Steven Cole; Moon Jung Song; Leming Tong; Ren Sun
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.